The drug industry lobby is arguing that the National Institutes of Health’s (NIH) first-ever proposal to use its licensing process to ensure medical products are affordable by keeping U.S. prices equal to those in other developed countries would discourage collaboration between NIH and the private sector. The health research agency published the policy proposal on May 21, and issued a request for information (RFI) from stakeholders on the approach. The drug maker lobby Pharmaceutical Research and Manufacturers of America (PhRMA)...